secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2022-07-06T23:59:59+00:00
Accession:  0001193125-22-188577
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Phase 2 breast cancer study: Arm A meets ORR endpoint but Arm B fails; program paused, partnership sought
--------------------------------------------------------------------------------

- Arm A in HR+/HER2- breast cancer met primary endpoint: ORR 15% (central review) in 47 patients unselected for CD166 expression.
- Arm B (TNBC) did not pass futility boundary (ORR <10%); enrollment in Arms B and C discontinued.
- Safety: 30% discontinued for AE; Grade 3+ ocular 15%, neuropathic 10%. Lower toxicity at 6 mg/kg dose.
- Company will not further advance program alone due to financial market conditions; seeking a partnership.
- CytomX intends to present full Phase 2 data at a medical conference in H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312522188577/0001193125-22-188577-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312522188577/d259130d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-188577

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer